San Diego Life Sciences Roundup: Allergan, Qualcomm Life, & More
(Page 3 of 3)
marketing its 2net Platform technology and services in Europe. In a statement, Qualcomm Life said two of its European customers, Italy’s Telbios and Spain’s Cystelcom, already are using the technology. Telbios provides remote health monitoring services for chronic care and disease management. Cystelcom, an engineering software development company, created mHealthAlert as an open remote monitoring platform for chronic disease patients to reduce readmissions and the length of their hospital stay.
—San Diego’s Auspex Pharmaceuticals, which just raised $25 million to fund late-stage trials of its deuterium-based analog of tetrabenazine (Xenazine), said a U.S. patent granted for SD-900, another drug in its pipeline, validates the company’s innovative approach to drug development. SD-900 is a deuterium-based analog of the JAK kinase inhibitor tofacitinib, approved by the FDA for treating rheumatoid arthritis. In a statement from Auspex, CEO Larry Fritz said, “The issuance of a composition-of-matter patent for SD-900 is strong validation of Auspex’s technological approach to the creation of important new drugs.”
—San Diego-based Illumina, (Nasdaq: ILMN) identified the winners of its MiSeq grant program, gleaned from nearly 850 applications submitted by scientists in more than 40 countries. They are: Ramunas Stepanauskas of Maine’s Bigelow Laboratory for Ocean Sciences, for sequencing single cells from unculturable strains of bacteria in the dark ocean; Stephen Doyle of La Trobe University in Melbourne, Australia, for investigating drug resistance in African river blindness; and Karin Haack of the Texas Biomedical Research Institute in San Antonio, TX, for targeted resequencing of genes implicated in cardiovascular disease. Each winner gets a MiSeq genetic sequencing machine and related products and services valued at more than $150,000.